Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
17 Cards in this Set
- Front
- Back
- 3rd side (hint)
|
Somatropin
Somatrem (GH) |
Growth hormone and insulin-like growth factor replacement
stimulates release of or replace GH or insulin-like growth factor |
caution in diabetes and in children whose GH deficiency results from intracranial lesion, available as depot injection, glucocorticoids inhibit growth-promoting effect of somatropin
|
|
|
Sermorelin (GHRH)
|
Growth hormone and insulin-like growth factor replacement
stimulates release of or replace GH or insulin-like growth factor |
caution in children whose GH deficiency results from intracranial lesion
|
|
|
Hexarelin
Ghrelin |
Growth hormone and insulin-like growth factor replacement
stimulates release of or replace GH or insulin-like growth factor |
experimental agents that bind to GH- secretagogue receptor, hexarelin formulations available for intranasal use
|
|
|
Mecasermin
|
Growth hormone and insulin-like growth factor replacement
stimulates release of or replace GH or insulin-like growth factor |
recombinant IGF-1, available as twice-daily and once-daily injections
|
|
|
Octreotide
|
agents that decrease GH secretion or action
inhibit GHRH release, antagonize GH receptor (pegvisomant) |
also used to control GI bleeding and to reduce secretory diarrhea, octreotide also available in depot formulation, decreases cyclosporine levels, lanretide similar agent available in Europe
|
|
|
Somatostatin
|
agents that decrease GH secretion or action
inhibit GHRH release, antagonize GH receptor (pegvisomant) |
upon discontinuation, may experience rebound hormonal hypersecretion, reduces analgesic effects of morphine
|
|
|
Pegvisomant
|
agents that decrease GH secretion or action
inhibit GHRH release, antagonize GH receptor (pegvisomant) |
patients shold hav yearly MRI to exclude enlarging adenoma
|
|
|
Bromocriptine
|
agents that decrease prolactin levels
inhibit pituitary prolactin release |
intravaginal administration may reduce GI side effects, alcohol intolerance may occur, first dose phenomenon occurs in 1% patients, coadministration with antihypertensives potentiates hypotension
|
|
|
Pergolide
Quinoglide Cabergoline |
agents that decrease prolactin levels
inhibit pituitary prolactin release |
caution in patients prone to arrhythmias and underlying psychiatric disorders, caution in patients with history of pleuritis, pleural effusion, pleural fibrosis, pericarditis, cardiac valvulopathy, retroperitoneal fibrosis, CNS depressants have additive effects, cabergoline less nausea than bromo. or pergo.
|
|
|
Protirelin (TRH)
|
agents that test thyroid function
TRH stimulates TSH release from pituitary, TSH stimulates thyroid gland |
transient changes in BP can occur immediately following admin
|
|
|
Thyrotropin (TSH)
|
agents that test thyroid function
TRH stimulates TSH release from pituitary, TSH stimulates thyroid gland |
|
|
|
corticotropin (ACTH)
cosyntropin (ACTH 1-24) |
agents that test adrenal function
stimulates adrenal cortisol and androgen production |
cosyntropin contains first 24 AA residues of ACTH, less antigenic and less likely to cause allergic rxns than corticotropin which contains all 39 AA of ACTH
counteract edema by low-sodium, high-potassium intake coadmin with NSAIDS increases risk of GI bleeding |
|
|
gonadorelin
|
agents that alter gonadotropin expression
continuous: inhibits LH and FSH release pulsatile: stimulates LH and FSH release |
normal response to gonadorelin testing indicates presence of functional pituitary gonadotropes
pulsatile form for stimulation of ovulation |
|
|
goserelin
histrelin leuprolide naferlin |
agents that alter gonadotropin expression
continuous: inhibits LH and FSH release pulsatile: stimulates LH and FSH release |
can initially increase testosterone and estrogen production
|
|
|
follitropin (rFSH)
urofollitropin (FSH) |
agents that alter gonadotropin expression
continuous: inhibits LH and FSH release pulsatile: stimulates LH and FSH release |
may result in multiple fetuses
|
|
|
ganirelix
cetrorelix abarelix |
agents that alter gonadotropin expression
GnRH receptor antagonist |
|
|
|
conivaptan
tolvaptan |
vasopressin antagonists
mixed V1/V2 receptor antagonists |
contraindicated to use conivaptan with P450 3A4 inhiitors
tolvaptan investigational agent specific for V2 receptor |
